STP et pharmacogénétique - 2
mercredi 25 juin 2025
Sessions parallèles
Sessions parallèles
•
S43
•
16h00
>
17h30
•
STP et pharmacogénétique - 2
•
IFPS - Amphi 2
Sessions parallèles
Modérateurs : Estelle AYME-DIETRICH (Strasbourg), Benjamin HENNART (Lille)
Conférence invitée
16h00 Pharmacogénétique et suivi thérapeutique pharmacologique du mavacamten - Elodie GAUTIER-VEYRET (Grenoble)
Communications orales
•
40
•
CO-049 - Population PK/PD modeling of levobupivacaine and ropivacaine for motor block in spinal anesthesia
>
T.
Thomas
Duflot
•
150
•
CO-050 - Model-informed precision dosing of daptomycin : a four-year experience report
>
S.
Sylvain
Goutelle
•
292
•
CO-051 - Area under the 24-hour valganciclovir concentration curve in renal transplant patients dosed every 48 hours. Sure, but which 24 hours? An in silico study
>
C.
Christine
LUNE
•
180
•
CO-052 - Ivacaftor – Tezacaftor – Elexacaftor Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure in Plasma and Brain Tissue in People with Cystic Fibrosis
>
C.
Clotilde
Vellat
•
190
•
CO-053 - Effect of alternative administrations on P2Y12 receptor inhibitors’ pharmacokinetics and pharmacodynamics: systematic review and meta-analysis
>
C.
Céline
Konecki
•
284
•
CO-054 - Adverse effects of hydroxychloroquine in systemic lupus erythematous: the predictive potential of pharmacogenetics
>
C.
Caroline
Berthot
|